John D. Minna, M.D.

Director, Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research; Professor, Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center

Dr. John D. Minna is Director of the Hamon Center for Therapeutic Oncology Research at The University of Texas Southwestern Medical Center at Dallas (UTSW), and Professor of Internal Medicine and Pharmacology. He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, and co-leads the Experimental Therapeutics Program for the UTSW Simmons Cancer Center. Minna has served on the Scientific Advisory Boards for several cancer centers, as well as for the National Cancer Institute and the Board of Directors for American Association for Cancer Research and American Society for Clinical Oncology. He received the Bristol Meyers Award for Lung Cancer Research, the Rosenthal Cancer Research Prize, the Alton Ochsner Award Relating Smoking and Disease, the American Society of Clinical Oncology Lifetime Scientific Achievement Award, the ASCO Statesman Award, Addario Lung Cancer Foundation Asclepios Award, United Against Lung Cancer (UALC), Caine Halter Hope Now Award for Lung Cancer Research, and Giants of Cancer Care Award. For over 25 years he has co-led a joint NCI SPORE in Lung Cancer between UTSW and the MD Anderson Cancer Center. Dr. Minna graduated from Stanford University School of Medicine, was a resident in medicine at Massachusetts General Hospital, a Research Associate at the National Institutes of Health, Chief of the Section of Somatic Cell Genetics and then Chief of the NCI-VA and NCI-Navy Medical Oncology Branches at the National Cancer Institute. Currently he is working with a team of UTSW and MDACC scientists to discover all of the “acquired vulnerabilities” in lung cancer and their associated predictive molecular signatures to provide a new functional classification of lung cancer and rationale therapeutics for all new lung cancer patients. As part of this he has trained many investigators in lung cancer research.

Mailing List Mailing List
Close Mailing List